Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase (TcGAPDH) (TcGAPDH)

Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase (TcGAPDH) is a pivotal enzyme in the glycolytic pathway of the protozoan parasite responsible for Chagas disease (UniProt: P22512). In kinetoplastid parasites like T. cruzi, the initial seven steps of glycolysis are sequestered within specialized peroxisome-like organelles called glycosomes, making this enzyme essential for the parasite's energy metabolism and survival (PubMed: 11061125). Because T. cruzi relies almost exclusively on glycolysis for ATP production during its proliferative and bloodstream stages, inhibiting TcGAPDH effectively starves the parasite of energy. Structural biology studies have revealed significant differences in the NAD+ binding pocket and the catalytic site between the parasite's glycosomal enzyme and the human cytosolic counterpart, which facilitates the design of selective inhibitors (PubMed: 25663131). Various natural and synthetic compounds, including chalcones, flavonoids, and anacardic acids, have demonstrated potent inhibitory activity against TcGAPDH in vitro. Targeting this enzyme remains a highly promising strategy for developing new chemotherapies for American trypanosomiasis, aiming to provide safer and more effective alternatives to current drugs like benznidazole and nifurtimox.

Other names

Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)gGAPDHGAPDHG3P_TRYCR

Inhibition of the enzymatic conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate by competing with the substrate or the NAD+ cofactor, thereby disrupting the glycolytic pathway and energy production in the parasite.